[关键词]
[摘要]
近视已成为全球日益严重的公共卫生问题，且其发病年龄逐渐年轻化，发病率逐年上升，尤其在青少年中更为显著。重复低强度红光治疗(RLRL)作为一种新兴的非侵入性干预手段，近年来引起了广泛关注，并显示出在近视控制中的潜力。文章综述了PI3K/AKT信号通路在RLRL中的作用，特别是通过内皮型一氧化氮合酶(eNOS)磷酸化机制促进脉络膜增厚的研究进展。脉络膜增厚被认为是近视控制的重要环节。PI3K/AKT/eNOS/NO信号通路的激活可能通过改善脉络膜血流和营养供应，延缓眼轴增长。尽管已有一定的基础与临床研究支持这一机制，但仍存在许多未解问题，如RLRL的具体作用机制、安全性及其在不同人群中的适用性等。文章系统梳理了相关研究进展，旨在为未来的研究提供参考，并探讨RLRL在近视防控中的应用前景。
[Key word]
[Abstract]
Myopia has become a growing public health issue globally, characterized by an earlier age of onset and a rising annual incidence rate, particularly among adolescents. Repeated low-intensity red light therapy(RLRL)has gained widespread attention in recent years as an emerging non-invasive intervention, showing promise for controlling myopia. This article examines the role of the PI3K/AKT signaling pathway in RLRL,specifically advances in promoting choroidal thickening via the phosphorylation mechanism of endothelial nitric oxide synthase(eNOS). Choroidal thickening is recognized as a critical part of myopia control. Activation of the PI3K/AKT/eNOS-NO signaling pathway may attenuate axial elongation by enhancing choroidal blood flow and nutrient supply. Although certain basic and clinical studies have supported this mechanism, many unresolved issues still remain, such as the specific mechanisms of RLRL action, its safety, and its applicability in different populations. This article systematically reviews the relevant research progress, aiming to provide a valuable reference for future studies and explore the application prospects of RLRL in myopia prevention and control.
[中图分类号]
[基金项目]
2024年度省科技计划项目(No.202401AY070001-289); 云南省卫生健康委员会医学领军人才培养计划(No.L2018018); 昆明医科大学2025年学位与研究生教育创新基金(No.2025S368)
